---
title: 'Degraders Upgraded: The Rise of PROTACs in Haematological Malignancies'
date: '2024-01-03'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38170175/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20240104170644&v=2.18.0
source: Blood
description: Targeted protein degradation (TPD) is a revolutionary approach to targeted
  therapy in hematological malignancies that potentially circumvents many constraints
  of existing small molecule inhibitors. Heterobifunctional proteolysis targets chimeras
  (PROTACs) are the leading TPD drug class, with numerous agents now in clinical trials
  for a range of blood cancers. PROTACs harness the cell intrinsic protein recycling
  infrastructure, the ubiquitin-proteasome system (UPS), to completely degrade ...
disable_comments: true
---
Targeted protein degradation (TPD) is a revolutionary approach to targeted therapy in hematological malignancies that potentially circumvents many constraints of existing small molecule inhibitors. Heterobifunctional proteolysis targets chimeras (PROTACs) are the leading TPD drug class, with numerous agents now in clinical trials for a range of blood cancers. PROTACs harness the cell intrinsic protein recycling infrastructure, the ubiquitin-proteasome system (UPS), to completely degrade ...